News
British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine ...
GSK to buy Boston Pharma’s efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD: London, UK Thursday, May 15, 2025, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results